US FDA approves Vanda Pharmaceuticals' motion sickness drug
30/12/2025 23:16
Dec 30 (Reuters) - The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' VNDA.O drug for the prevention of vomiting induced by motion, the company said on Tuesday. (Reporting by Siddhi Mahatole and Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Vanda Pharmaceuticals
See all newsUS STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
US STOCKS ON THE MOVE-Nvidia, Penske Automotive, ManpowerGroup
US STOCKS ON THE MOVE-Barrick Mining, Venture Global, GE Vernova
Vanda Pharma shares slip as trial failure halts anxiety drug program